Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBIO Crescent Biopharma	$13.93 +0.2%	$13.88	$10.83 ▼ $63.00	$271.74M	1.51	99,914 shs	56,604 shs
LXRX Lexicon Pharmaceuticals	$1.18 +6.3%	$0.98	$0.28 ▼ $2.18	$403.37M	1.17	3.00 million shs	3.33 million shs
SGMO Sangamo Therapeutics	$0.54 +0.1%	$0.52	$0.41 ▼ $3.18	$125.82M	1.18	7.40 million shs	6.87 million shs
XOMA XOMA Royalty	$31.59 +2.3%	$26.28	$18.35 ▼ $35.00	$369.66M	1	30,294 shs	93,756 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBIO Crescent Biopharma	+0.22%	+26.64%	+18.65%	-98.18%	-98.18%
LXRX Lexicon Pharmaceuticals	+6.31%	+5.36%	+2.61%	+120.48%	-28.05%
SGMO Sangamo Therapeutics	+0.07%	+11.89%	+12.45%	+14.89%	-40.66%
XOMA XOMA Royalty	+2.27%	+22.25%	+20.30%	+17.04%	+20.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CBIO Crescent Biopharma	3.9721 of 5 stars	4.7	0.0	3.7	3.3	1.7	0.6
LXRX Lexicon Pharmaceuticals	2.9859 of 5 stars	3.3	3.0	0.0	3.3	2.5	0.6
SGMO Sangamo Therapeutics	2.819 of 5 stars	3.3	4.0	0.0	3.0	0.8	0.6
XOMA XOMA Royalty	4.4782 of 5 stars	3.5	4.0	3.0	3.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBIO Crescent Biopharma	3.40	Buy	$25.50	83.06% Upside
LXRX Lexicon Pharmaceuticals	2.50	Moderate Buy	$3.23	173.31% Upside
SGMO Sangamo Therapeutics	2.67	Moderate Buy	$4.50	733.33% Upside
XOMA XOMA Royalty	3.00	Buy	$69.50	120.01% Upside

Current Analyst Ratings Breakdown

Latest SGMO, LXRX, XOMA, and CBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	CBIO Crescent Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
8/7/2025	LXRX Lexicon Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1.20 ➝ $1.90
7/14/2025	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
6/25/2025	CBIO Crescent Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$28.00
6/24/2025	LXRX Lexicon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/24/2025	SGMO Sangamo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/20/2025	CBIO Crescent Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/18/2025	CBIO Crescent Biopharma	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$22.00
5/28/2025	XOMA XOMA Royalty	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$104.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBIO Crescent Biopharma	$10K	27,233.15	N/A	N/A	$6.92 per share	2.01
LXRX Lexicon Pharmaceuticals	$31.08M	13.80	N/A	N/A	$0.36 per share	3.28
SGMO Sangamo Therapeutics	$57.80M	2.18	N/A	N/A	$0.08 per share	6.75
XOMA XOMA Royalty	$28.49M	13.27	N/A	N/A	$6.95 per share	4.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBIO Crescent Biopharma	-$37.88M	-$34.93	N/A	N/A	N/A	N/A	-106.06%	-86.60%	N/A
LXRX Lexicon Pharmaceuticals	-$200.40M	-$0.33	N/A	N/A	N/A	-206.43%	-83.63%	-42.22%	N/A
SGMO Sangamo Therapeutics	-$97.94M	-$0.29	N/A	N/A	N/A	-77.48%	-293.05%	-63.85%	N/A
XOMA XOMA Royalty	-$13.82M	-$1.55	N/A	N/A	N/A	-27.57%	2.54%	0.97%	N/A

Latest SGMO, LXRX, XOMA, and CBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	XOMA XOMA Royalty	-$0.12	$0.48	+$0.60	$0.44	$9.39 million	$13.13 million
8/7/2025	Q2 2025	SGMO Sangamo Therapeutics	-$0.07	-$0.08	-$0.01	-$0.08	$31.68 million	$18.31 million
8/6/2025	Q2 2025	LXRX Lexicon Pharmaceuticals	-$0.08	$0.01	+$0.09	$0.01	$4.87 million	$28.87 million
7/31/2025	Q2 2025	CBIO Crescent Biopharma	-$2.69	-$4.93	-$2.24	-$4.93	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A
XOMA XOMA Royalty	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBIO Crescent Biopharma	N/A	9.21	9.21
LXRX Lexicon Pharmaceuticals	0.43	4.16	4.16
SGMO Sangamo Therapeutics	N/A	1.05	1.05
XOMA XOMA Royalty	1.18	5.54	5.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CBIO Crescent Biopharma	75.19%
LXRX Lexicon Pharmaceuticals	74.70%
SGMO Sangamo Therapeutics	56.93%
XOMA XOMA Royalty	95.92%

Insider Ownership

Company	Insider Ownership
CBIO Crescent Biopharma	4.00%
LXRX Lexicon Pharmaceuticals	13.90%
SGMO Sangamo Therapeutics	4.10%
XOMA XOMA Royalty	9.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CBIO Crescent Biopharma	50	19.55 million	18.77 million	No Data
LXRX Lexicon Pharmaceuticals	140	363.40 million	312.89 million	Optionable
SGMO Sangamo Therapeutics	480	233.17 million	223.61 million	Optionable
XOMA XOMA Royalty	10	11.97 million	10.88 million	Optionable

SGMO, LXRX, XOMA, and CBIO Headlines

Recent News About These Companies

LAVA Therapeutics Announces Acquisition by XOMA Corporation

August 14 at 5:28 PM | tipranks.com

Xoma Corp. Reports Strong Earnings Growth in 2025

August 14 at 4:26 AM | msn.com

LAVA Therapeutics Enters Agreement to Be Acquired by XOMA Royalty Corporation and Announces Discontinuation of LAVA-1266 Development

August 13 at 5:42 PM | quiverquant.comQ

Cautious Hold Rating on Xoma Amid Strategic Acquisitions and Uncertain Growth Outlook

August 13 at 11:42 AM | tipranks.com

XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates

August 13 at 9:55 AM | zacks.com

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

August 13 at 7:30 AM | globenewswire.com

XOMA Royalty Corporation: XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

August 11, 2025 | finanznachrichten.de

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

August 11, 2025 | finance.yahoo.com

XOMA Royalty (XOMA) Projected to Post Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

XOMA Royalty (NASDAQ:XOMA) Upgraded to "Buy" at Wall Street Zen

August 11, 2025 | marketbeat.com

Institutional investors own a significant stake of 43% in XOMA Royalty Corporation (NASDAQ:XOMA)

August 10, 2025 | finance.yahoo.com

CM Management LLC Grows Stake in XOMA Royalty Corporation (NASDAQ:XOMA)

August 7, 2025 | marketbeat.com

XOMA Royalty (XOMA) Projected to Post Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

I'm Staying Neutral On XOMA Royalty After The LAVA And HilleVax Deals

August 6, 2025 | seekingalpha.com

HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

August 5, 2025 | businesswire.com

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.

August 5, 2025 | prnewswire.com

Hold Rating on XOMA’s Acquisition of LAVA Therapeutics: Valuation and Risks Assessed

August 5, 2025 | tipranks.com

XOMA Royalty (NASDAQ:XOMA) Cut to "Hold" at Wall Street Zen

August 5, 2025 | americanbankingnews.com

LAVA Therapeutics stock rises on acquisition deal with XOMA Royalty

August 4, 2025 | investing.com

Hillevax stock rises after XOMA Royalty announces acquisition

August 4, 2025 | investing.com

XOMA Royalty Corporation Enters Definitive Share Purchase Agreement to Acquire LAVA Therapeutics N.V.

August 4, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO, LXRX, XOMA, and CBIO Company Descriptions

Crescent Biopharma NASDAQ:CBIO

$13.93 +0.03 (+0.22%)

As of 08/14/2025 04:00 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.18 +0.07 (+6.31%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.18 0.00 (0.00%)

As of 04:04 AM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Sangamo Therapeutics NASDAQ:SGMO

$0.54 +0.00 (+0.07%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.54 0.00 (-0.19%)

As of 04:05 AM Eastern

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

XOMA Royalty NASDAQ:XOMA

$31.59 +0.70 (+2.27%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$31.58 -0.01 (-0.03%)

As of 08/14/2025 04:20 PM Eastern

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time